Marrow Hypocellularity, but Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients with Morphologic Residual Disease

Induction chemotherapy for acute myeloid leukemia (AML) is based on the “7+3” cytarabine/anthracycline regimen. A non hypocellular day 14 (D14) marrow with a blast count greater than 5-10% is suggestive of residual leukemia for which a second course of induction chemotherapy is recommended. Although the prognostic value of D14 marrow has been established, its use as a decision point is controversial as the benefit of repeat induction is questionable. In this single-center retrospective study of 113 patients with newly diagnosed AML, we evaluated the role of cellularity on clinical outcomes in patients with residual morphologic leukemia (blasts ≥5%).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research